



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	09/299139-Conf. #2882
				Filing Date	April 23, 1999
				First Named Inventor	Jeffrey L. BROWNING
				Art Unit	1643
				Examiner Name	C. H. Yaen
Sheet	1	of	1	Attorney Docket Number	BGN-A013RCE

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
CY	B1	WO-92/00329-A1	01-09-1992	Biogen, Inc., et al.		
CY	B2	WO-94/13808-A2	06-23-1994	Biogen, Inc., et al.		
CY	B3	WO-97/03687-A1	02-06-1997	Biogen, Inc.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
CY	C1	<a href="http://reutershealth.com/wellconnected/doc63.html">http://reutershealth.com/wellconnected/doc63.html</a>		
	C2	Browning, Jeffrey L., et al., "Signaling through the Lymphotoxin $\beta$ Receptor Induces the Death of Some Adenocarcinoma Tumor Lines," <i>J. Exp. Med.</i> , Vol. 183:867-878 (1996) ✓		
	C3	Browning, Jeffrey L., et al., "Characterization of Surface Lymphotoxin Forms," <i>The Journal of Immunology</i> , Vol. 154:33-46 (1995) ✓		
	C4	Gyorfy, Zs., et al., "Alteration of the TNF Sensitivity and Membrane Viscosity of Target Cells," <i>Eur. Cytokine Netw.</i> , Vol. 7(2):167 (1996) ✓		
	C5	Mendlovic, Shlomo, et al., "Induction of a Systemic Lupus Erythematosus-like Disease in Mice by a Common Human Anti-DNA Idiotype," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 85:2260-2264 (1988)		
	C6	Rennert, P.D., et al., "Normal Development of Lymph Nodes is Disrupted by Soluble LT beta Receptor - Ig Fusion Protein," <i>Eur. Cytokine Netw.</i> , Vol. 7(2):167 (1996) ✓		
	C7	Smolen, Josef S., "Therapy of systemic lupus erythematosus: a look into the future," <i>Arthritis Res.</i> , Vol. 4(suppl. 3):S25-S30 (2002)		
	C8	Trethewey, Pat, "Systemic Lupus Erythematosus," <i>Dimensions of Critical Care Nursing</i> , Vol. 23(3):111-115 (2004)		
CY	C9	International Search Report Docket No. PCT/US97/19436, dated May 28, 1998 ✓		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Christopher Yaen/ (09/28/2006)	Date Considered	09/28/2006
-----------------------	---------------------------------	--------------------	------------